Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer
Francesco Caponigro, P. Fumoleau(Institut Curie), Jakob B. Sørensen(University of Copenhagen), Florence Duffaud(Aix-Marseille Université), Luis Paz Ares(European Organisation for Research and Treatment of Cancer), Denis Lacombe(European Organisation for Research and Treatment of Cancer), Jan H.M. Schellens(Utrecht University), Christine de Balincourt(Fondazione Vincenzo Pansadoro), Christian Dittrich(Leibniz Institute for Agricultural Engineering and Bioeconomy)
Cited by 28
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924
|Journal of Clinical Oncology|2001|628